Oxurion NV in brief
Oxurion NV is a listed company in the Biotechnology industry, based in Belgium. Its last known market value was $3 M (January 2024); there is no current figure. In the year to December 2023 it had sales of $0 M and a net loss of $20 M. Its shares trade under the symbol OXUR.BR (EURONEXT).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Oxurion NV timeline
- 2006
- 🏁· approximateIncorporated as Oxurion
- 2016
- •Legal Entity Identifier issuedLEI 549300VWY8KVDFKLDM59 registered.
Events of Oxurion NV from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Belgium: #83 (Jan 2020) · #83 (Jan 2021) · #101 (Jan 2022) · #111 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -7321.4%
- Operating margin
- -4675.0%
- Return on equity
- —
- Liabilities / assets
- 301.2%
- Revenue growth
- -55.6%
- R&D / revenue
- 3857.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | $0M | -55.6% | $-13M | $-21M | -7321.4% |
| Dec 2022 | $1M | — | $-24M | $-33M | -5285.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-11M | $0M | $-11M | — | — |
| Dec 2022 | $-20M | $0M | $-20M | — | — |
Annual results
- Revenue
- $0 M
- Operating income
- $-13 M
- Net income
- $-21 M
For year ending December-2023 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $22 M
- Total equity
- $-15 M
As of December-2023
Oxurion NV scorecard#
Passes 0 of the 1 checks that could be worked out. Fiscal year 2023.
Valuationnot known
Growthnot known
Profitability0 of 1
Financial healthnot known
Shareholder returnsnot known
Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Oxurion NV: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 263 | 595 | 1,128 | 2,078 | |
| Cost of revenue | 159 | 513 | 612 | 550 | |
| Gross profit | 104 | 82 | 516 | 1,528 | |
| Research and development | 9,987 | 15,986 | 20,696 | 22,053 | |
| Selling and marketing | — | — | 1,274 | 3,252 | |
| Operating income | −12,110 | −22,946 | −28,495 | −28,620 | |
| Interest and finance income | 414 | 639 | 171 | 468 | |
| Interest expense and finance costs | 7,270 | 9,379 | 1,268 | 408 | |
| Provision for credit losses | — | — | 1,127 | 125 | |
| Income before tax | −18,966 | −31,686 | −29,592 | −28,560 | |
| Income tax | 3.0 | 7.0 | 3.0 | 0 | |
| Net income including minority interests | −18,969 | −31,693 | −29,595 | −28,560 | |
| Minority interests' share of net income | 0 | −8.0 | −437 | −548 | |
| Net income attributable to shareholders | −18,969 | −31,685 | −29,158 | −28,012 | |
| Earnings per share, basic | -0.01 | -0.37 | -0.77 | -0.75 | |
| Earnings per share, diluted | -0.01 | -0.37 | -0.77 | -0.75 | |
| Balance sheet | |||||
| Cash and cash equivalents | 1,624 | 3,496 | 9,740 | 24,511 | |
| Inventory | 0 | 5.0 | — | — | |
| Current assets | 2,740 | 7,106 | 13,409 | 27,054 | |
| Property, plant and equipment | 57 | 99 | 120 | 230 | |
| Right-of-use (leased) assets | 188 | 963 | 252 | 1,069 | |
| Other intangible assets | 0 | 0 | 1,000 | 2,127 | |
| Non-current assets | 3,810 | 4,887 | 5,467 | 7,230 | |
| Total assets | 6,550 | 11,993 | 18,876 | 34,284 | |
| Current liabilities | 19,607 | 12,349 | 10,913 | 7,693 | |
| Lease liabilities (non-current) | 117 | 833 | 44 | 447 | |
| Non-current liabilities | 129 | 4,227 | 9,071 | 1,543 | |
| Retained earnings | −92,373 | −73,404 | −41,719 | −12,561 | |
| Shareholders' equity | −13,186 | −4,583 | −1,078 | 25,180 | |
| Minority interests | 0 | 0 | −30 | −132 | |
| Total equity | −13,186 | −4,583 | −1,108 | 25,048 | |
| Total liabilities and equity | 6,550 | 11,993 | 18,876 | 34,284 | |
| Cash-flow statement | |||||
| Share-based compensation | 316 | 933 | 1,107 | 458 | |
| Cash from operating activities | −9,765 | −19,379 | −26,978 | −27,079 | |
| Capital expenditure | −1.0 | −59 | −32 | −119 | |
| Cash from investing activities | 72 | 111 | 407 | 10,064 | |
| Debt issued | — | — | 11,150 | 0 | |
| Debt repaid | −4,498 | −3,605 | — | — | |
| Shares issued | — | — | 1,350 | 0 | |
| Cash from financing activities | 7,822 | 13,001 | 11,778 | −931 | |
| Exchange-rate effect on cash | 1.0 | 23 | 22 | −35 | |
| Change in cash | −1,871 | −6,267 | −14,793 | −17,946 | |
| Report | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2023
How Oxurion NV compares in Biotechnology
- Revenue$0 M · higher than 19% of 647
- Revenue growth-55.6% · higher than 16% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Oxurion NV🇧🇪 | $3 M | — | — | -55.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Profile updated:
- Nov 15, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Oxurion NV? Verify and update this profile — free
Show Oxurion NV's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.